Allison Bratzel
Stock Analyst at Piper Sandler
(4.43)
# 240
Out of 4,826 analysts
37
Total ratings
64.29%
Success rate
15.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $38.87 | +195.86% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $2.35 | +155.86% | 1 | Mar 14, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $30 → $23 | $1.49 | +1,448.82% | 1 | Mar 11, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $3.68 | +606.52% | 1 | Feb 18, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $620 → $725 | $656.65 | +10.41% | 13 | Jan 7, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $21.42 | +2.71% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $19.11 | +20.36% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $33.61 | +84.47% | 1 | Nov 14, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 → $42 | $32.53 | +29.11% | 3 | Oct 15, 2024 | |
| ROIV Roivant Sciences | Maintains: Overweight | $20 → $22 | $11.58 | +90.06% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.26 | +217.46% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $4.24 | +371.70% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $2.19 | +813.24% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $44 | $10.03 | +338.68% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $62.11 | +61.00% | 2 | Feb 8, 2023 |
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $38.87
Upside: +195.86%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $2.35
Upside: +155.86%
Inozyme Pharma
Mar 11, 2025
Maintains: Overweight
Price Target: $30 → $23
Current: $1.49
Upside: +1,448.82%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $3.68
Upside: +606.52%
argenx SE
Jan 7, 2025
Maintains: Overweight
Price Target: $620 → $725
Current: $656.65
Upside: +10.41%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $21.42
Upside: +2.71%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $19.11
Upside: +20.36%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $33.61
Upside: +84.47%
Scholar Rock Holding
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $32.53
Upside: +29.11%
Roivant Sciences
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.58
Upside: +90.06%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.26
Upside: +217.46%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $4.24
Upside: +371.70%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $2.19
Upside: +813.24%
Apr 17, 2023
Assumes: Overweight
Price Target: $44
Current: $10.03
Upside: +338.68%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $62.11
Upside: +61.00%